The effect of angiotensin II on blood pressure in patients with circulatory shock: A structured review of the literature
PublisherBioMed Central Ltd.
MetadataShow full item record
AbstractBackground: Circulatory shock is a common syndrome with a high mortality and limited therapeutic options. Despite its discovery and use in clinical and experimental settings more than a half-century ago, angiotensin II (Ang II) has only been recently evaluated as a vasopressor in distributive shock. We examined existing literature for associations between Ang II and the resolution of circulatory shock. Methods: We searched PubMed, MEDLINE, Ovid, and Embase to identify all English literature accounts of intravenous Ang II in humans for the treatment of shock (systolic blood pressure [SBP] ≤ 90 mmHg or a mean arterial pressure [MAP] ≤ 65 mmHg), and hand-searched the references of extracted papers for further studies meeting inclusion criteria. Of 3743 articles identified, 24 studies including 353 patients met inclusion criteria. Complete data existed for 276 patients. Extracted data included study type, publication year, demographics, type of shock, dosing of Ang II or other vasoactive medications, and changes in BP, lactate, and urine output. BP effects were grouped according to type of shock, with additional analyses completed for patients with absent blood pressure. Shock was distributive (n = 225), cardiogenic (n = 38), or from other causes (n = 90). Blood pressure as absent in 18 patients. Results: For the 276 patients with complete data, MAP rose by 23.4% from 63.3 mmHg to 78.1 mmHg in response to Ang II (dose range: 15 ng/kg/min to 60 mcg/min). SBP rose by 125.2% from 56.9 mmHg to 128.2 mmHg (dose range: 0.2 mcg/min to a 1500 mcg bolus). A total of 271 patients with complete data were determined to exhibit a BP effect which was directly associated with Ang II. Subgroups (patients with cardiogenic, septic, and other types of shock) exhibited similar increases in BP. In patients with absent BP, deemed to be cardiac arrest, return of spontaneous circulation (ROSC) was achieved, and BP increased by an average of 107.3 mmHg in 11 of 18 patients. The remaining seven patients with cardiac arrest did not respond. Conclusions: Intravenous Ang II is associated with increased BP in patients with cardiogenic, distributive, and unclassified shock. A role may exist for Ang II in restoring circulation in cardiac arrest. Copyright 2017 The Author(s).
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85039543404&doi=10.1186%2fs13054-017-1896-6&partnerID=40&md5=0ae8bf4298833624b481ca70667ad77e; http://hdl.handle.net/10713/9982
- Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study.
- Authors: Chawla LS, Busse L, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z, Seneff MG
- Issue date: 2014 Oct 6
- FDA Approval of Angiotensin II for the Treatment of Hypotension in Adults with Distributive Shock.
- Authors: Senatore F, Jagadeesh G, Rose M, Pillai VC, Hariharan S, Liu Q, McDowell TY, Sapru MK, Southworth MR, Stockbridge N
- Issue date: 2019 Feb
- Comparison of angiotensin II-induced blood pressure and structural changes in Fischer 344 and Wistar Kyoto rats.
- Authors: Blanc J, Lacolley P, Laurent S, Elghozi JL
- Issue date: 2004 Jul
- Hemodynamic basis for the limited renal injury in rats with angiotensin II-induced hypertension.
- Authors: Polichnowski AJ, Griffin KA, Picken MM, Licea-Vargas H, Long J, Williamson GA, Bidani AK
- Issue date: 2015 Feb 1
- Angiotensin II-induced changes in G-protein expression and resistance of renal microvessels in young genetically hypertensive rats.
- Authors: Vyas SJ, Blaschak CM, Chinoy MR, Jackson EK
- Issue date: 2000 Sep